| Literature DB >> 17324259 |
Stefan Toegel1, Wenwen Huang, Claudia Piana, Frank M Unger, Michael Wirth, Mary B Goldring, Franz Gabor, Helmut Viernstein.
Abstract
BACKGROUND: Chondroprotective agents (CPA) such as glucosamine, curcumin and diacerein represent potential remedies for the management of osteoarthritis and several studies have been performed on their effects in-vitro and in-vivo. For the investigation of chondroprotective action on chondrocyte gene expression, quantitative real-time RT-PCR is the method of choice. However, validation of applied normalization strategies represents a crucial and sometimes neglected step in the analysis process. Therefore, the present study aimed to determine the expression stability of common reference genes (ACTB, Beta actin; GAPDH, Glyceraldehyde-3-phosphate; B2M, Beta-2-microglobulin; HPRT1, Hypoxanthine phosphoribosyl-transferase I; SDHA, Succinate dehydrogenase complex, subunit A; YWHAZ, Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) under the influence of glucosamine, curcumin and diacerein in the IL-1beta-stimulated C-28/I2 chondrocyte model, using the geNorm software tool.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17324259 PMCID: PMC1820791 DOI: 10.1186/1471-2199-8-13
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
Function of reference genes, primer sequences, optimal primer concentrations and reaction efficiencies of qPCR experiments.
| ACTB | Cytoskeletal structural protein | fw: CTGGAACGGTGAAGGTGACA | 300 | 1.94 ± 0.01 |
| GAPDH | Oxidoreductase in glycolysis and gluconeogenesis | fw: GGAGTCCACTGGCGTCTTCAC | 300 | 1.94 ± 0.01 |
| B2M | Beta-chain of major histocompatibility complex class I molecules | fw: TGCTGTCTCCATGTTTGATGTATCT | 300 | 2.03 ± 0.04 |
| HPRT1 | Purine synthesis in salvage pathway | fw: TGACACTGGCAAAACAATGCA | 300 | 1.94 ± 0.03 |
| SDHA | Electron transporter in the TCA cycle and respiratory chain | fw: TGGGAACAAGAGGGCATCTG | 300 | 2.00 ± 0.01 |
| YWHAZ | Signal transduction by binding to phosphorylate serine residues | fw: ACTTTTGGTACATTGTGGCTTCAA | 600 | 1.98 ± 0.01 |
Optimal primer concentrations were determined using a matrix of forward and reverse primers varying in concentration from 50 nM to 900 nM. Combinations that gave the lowest Ct value and the highest ΔRn value were selected. qPCR efficiencies for each primer pair were derived from standard curves (n = 3) using five-fold dilution series covering a 4 to 5 log dynamic range starting from one randomly selected undiluted cDNA sample of the untreated control group.
Figure 1qPCR cycle threshold values of 6 reference genes among 7 culture conditions (table 2). Distribution of expression levels of ACTB, GAPDH, B2M, HPRT1, SDHA, and YWHAZ in IL-1β treated C-28/I2 chondrocytes under the influence of glucosamine (A), curcumin (B) and diacerein (C) is shown as medians (lines), 25th percentile to the 75th percentile (boxes) and ranges (whiskers) (n = 63). Samples were normalized to the amount of total RNA.
Experimental design
| Experimental condition | Supplements on days of culture | |
| day 5 | day 6 | |
| Control | - | - |
| IL-1β | - | IL-1β |
| Simultaneous incubation with CPA [c]1 | - | [c]1+IL-1β |
| Simultaneous incubation with CPA [c]2 | - | [c]2+IL-1β |
| Pre-incubation with CPA [c]1 | [c]1 | [c]1+IL-1β |
| Pre-incubation with CPA [c]2 | [c]2 | [c]2+IL-1β |
| CPA only | [c]2 | [c]2 |
Supplements added to the chondrocyte culture medium on days 5 and 6 of the culture period are presented. Either glucosamine, curcumin or diacerein were used as chondroprotective agent (CPA) in 3 separate experiments. Each experiment followed the presented setup of 7 different study groups.
IL-1β, 10 ng/ml recombinant human interleukin-1beta; [c]1, low concentration of glucosamine (50 μM), curcumin (5 μM) or diacerein (5 μM); [c]2, high concentration of glucosamine (5 mM), curcumin (50 μM) or diacerein (50 μM).
Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and glucosamine.
| IL-1β | 1.05 ± 0.27 | 1.14 ± 0.22 | 1.08 ± 0.24 | 1.00 ± 0.20 | 0.88 ± 0.16 | |
| Simultaneous incubation with glucosamine [c]1 | 1.27 ± 0.24 | 1.13 ± 0.18 | 0.93 ± 0.13 | 0.83 ± 0.14 | 0.83 ± 0.15 | |
| Simultaneous incubation with glucosamine [c]2 | 1.04 ± 0.11 | |||||
| Pre-incubation with glucosamine [c]1 | 0.87 ± 0.11 | 0.97 ± 0.25 | 1.11 ± 0.22 | 1.02 ± 0.11 | 0.74 ± 0.10 | |
| Pre-incubation with glucosamine [c]2 | ||||||
| Glucosamine only | 0.77 ± 0.34 | |||||
Boldfaced values p < 0.05
*p < 0.05 and change > 2-fold
mRNA levels under the treatment with glucosamine in different experimental conditions are presented relative to the untreated control group calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low concentration of glucosamine (50 μM); [c]2, high concentration of glucosamine (5 mM).
Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and curcumin.
| IL-1β | 0.93 ± 0.16 | 0.86 ± 0.10 | 1.06 ± 0.17 | 0.97 ± 0.15 | 0.91 ± 0.11 | 0.92 ± 0.13 |
| Simultaneous incubation with curcumin [c]1 | 0.88 ± 0.11 | |||||
| Simultaneous incubation with curcumin [c]2 | 0.89 ± 0.16 | |||||
| Pre-incubation with curcumin [c]1 | 0.87 ± 0.13 | 0.98 ± 0.15 | 0.94 ± 0.18 | 0.97 ± 0.11 | 0.95 ± 0.23 | 1.02 ± 0.21 |
| Pre-incubation with curcumin [c]2 | ||||||
| Curcumin only | ||||||
Boldfaced values p < 0.05
* p < 0.05 and change > 2-fold
mRNA levels under the treatment with curcumin in different experimental conditions are presented relative to the untreated control group calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low concentration of curcumin (5 μM); [c]2, high concentration of curcumin (50 μM).
Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and diacerein.
| IL-1β | 1.2 ± 0.57 | 1.10 ± 0.08 | 1.23 ± 0.46 | 1.02 ± 0.66 | 0.89 ± 0.45 | |
| Simultaneous incubation with diacerein [c]1 | 1.03 ± 0.39 | 1.11 ± 0.40 | 1.36 ± 0.29 | 1.26 ± 0.40 | 1.13 ± 0.34 | 1.14 ± 0.43 |
| Simultaneous incubation with diacerein [c]2 | 0.71 ± 0.18 | 1.02 ± 0.21 | 1.15 ± 0.20 | 1.07 ± 0.25 | 0.88 ± 0.17 | 0.69 ± 0.17 |
| Pre-incubation with diacerein [c]1 | 1.21 ± 0.21 | 1.12 ± 0.33 | 1.23 ± 0.57 | 1.29 ± 0.40 | 1.35 ± 0.39 | 1.11 ± 0.31 |
| Pre-incubation with diacerein [c]2 | 0.79 ± 0.11 | 0.96 ± 0.12 | 1.00 ± 0.13 | 0.98 ± 0.19 | 0.7 ± 0.15 | |
| Diacerein only | 0.63 ± 0.10 | 0.73 ± 0.09 | 0.87 ± 0.15 | 0.88 ± 0.15 | ||
Boldfaced values p < 0.05
* p < 0.05 and change > 2-fold
mRNA levels under the treatment with diacerein in different experimental conditions are presented relative to the untreated control group calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low concentration of diacerein (5 μM); [c]2, high concentration of diacerein (50 μM).
Ranking of the reference genes as determined using the geNorm software tool.
| Glucosamine | Curcumin | Diacerein |
| SDHA | ||
| ACTB | YWHAZ | |
| ACTB | YWHAZ | SDHA |
| YWHAZ | SDHA | ACTB |
The genes are ranked in order of their expression stability under the influence of glucosamine, curcumin and diacerein decreasing from top to bottom. The 2 most stable reference genes in each experiment cannot be ranked in order due to the required use of ratios for the calculation of gene expression stability. The reference genes proposed for comparing the 3 chondroprotective agents are displayed in bold letters.